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Abstract
Human leukocyte antigen (HLA) is a group of 
proteins coded by the major histocompatibility 
complex (MHC) and is a vital part of the human 
immune response. HLA allows abnormal cells 
to be destroyed by cytotoxic T-cells by 
presenting antigens to the cell surface. In 
tumors, however, there is diminished HLA 
expression, allowing cells to bypass the 
immune system. Experiments were conducted 
to determine the effects of various drug 
epigenetic modifiers on HLA expression in 
MDA-MB-231 cells, a human breast cancer cell 
line. HLA expression was compared between 
control and drug treatments using flow 
cytometry. Initial results found that HLA-ABC 
expression is increased in cells treated 
individually with the drugs 5-Azacytidine and 
Vorinostat. We are continuing to test 
combinations of these drugs, along with the 
addition of gamma-Interferon, an immune 
cytokine known to upregulate HLA-ABC 
expression. Furthermore, we would like to 
study how two other HLA proteins, HLA-E and 
HLA-G, can be affected by these epigenetic 
modifiers. Effective increases in HLA 




Cells grown in 25 cm2 with 
Iscove's Modified Dulbecco's Medium  
Methods
Treatment Selection
Control and experimental flasks made 
Flow Cytometry
HLA-ABC analyzed via flow cytometry
Treatment Marking
Anti-HLA Class I antibodies added to 






I would like to thank Dr. O’Donnell for his 
continuous help and mentorship throughout 
my research with him. I would also like to 
thank the other members of the O’Donnell 
lab for their assistance, as well as the SUNY 
Geneseo Biology Department for providing 

















































Table 1. Flow Cytometry Fluorescence of 
HLA-ABC, shown as mean log values. 
A variety of treatments were done across 5 
separate experiments. Treatments that were not 
applied are noted as a dash (–). Every trial 
shows a clear increase in HLA expression from 
each experimental treatment. For each drug 
treatment, percent increase relative to the 
control is shown.
Figure 1. Flow cytometry 
fluorescence of HLA-ABC 
in MDA-MB-231 treated 
with 5-Azacytidine. A 
strong increase in HLA 
expression is shown as a 
result of the drug treatment. 
Figure 2. Flow cytometry 
fluorescence of HLA-ABC 
in MDA-MB-231 treated 
with Vorinostat. A 
noticeable increase in HLA 
expression is shown as a 
result of the drug treatment. 
• Previous experimentation in cancer 
immunotherapy have demonstrated that 
tumor cells are able to proliferate via 
downregulation of MHC class I, thus 
bypassing a T cell-mediated immune 
response [1]. 
• Vorinostat and interferons have been 
shown to restore HLA expression in 
Merkel cell carcinoma [2].
• DNA methyltransferase (DNMT) 
inhibitors like 5-Azacytidine have been 
found to lack curative effects but still 
enhance the activity of cytotoxic drugs 
for treating acute myeloid leukemia and 
lung cancer [3]
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• 5-Azacytidine and Vorinostat both 
individually upregulate HLA-expression 
in MDA-MB-231.
• Gamma Interferon also demonstrated a 
strong upregulation in HLA-ABC 
expression (Table 1).
• Although a combination of Gamma 
Interferon and Vorinostat was found to 
augment expression, a combination of 
Gamma Interferon with 5-Azacytidine 
lowered expression below those of 
individual drug treatments alone, while 
still above that of control conditions 
(Figures 3 and 4).
Figure 3. Flow cytometry fluorescence of HLA-ABC in 
MDA-MB-231 under different conditions. Control (no 
drug) is represented by purple, IFNγ is represented by light 
green, and IFNγ with 5-Azacytidine is represented by pink.
Figure 4. Flow cytometry fluorescence of HLA-ABC in 
MDA-MB-231 under different conditions. Control (no 
drug) is represented by purple, Vorinostat is represented by 
light green, IFNγ is represented by pink, and IFNγ with 
Vorinostat is represented by blue. 
• We would like to investigate into other 
components of MHC Class I, such as 
HLA-G and HLA-E.
• Moreover, we are interested in 
investigating HLA expression of MHC 
Class II, as it has been speculated that the 
upregulation of MHC Class II in tumor 
cell lines may improve chances of 
recognition by the immune system [4]
